Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
LONDON - Ananda Pharma plc (AQSE:ANA, OTC: ANANF) announced Tuesday that CEO Melissa Sturgess will attend the 8th Cannabinoid & Endocannabinoid Drug Development Summit in Boston on October 15-16.
According to a company press release, Sturgess will deliver a presentation on October 15 titled "Advancing Botanical Cannabidiol Drugs: Insights from Endometriosis Clinical Development." The presentation will outline Ananda’s approach to CBD drug development using naturally derived CBD isolate, the case for higher dosing over bioavailability modifications, and the company’s endometriosis program as a case study.
Following her presentation, Sturgess will participate in a panel discussion focused on cannabinoid-based therapies for women’s health. The panel will address strategies for engaging patients and clinicians, regulatory barriers limiting patient access, and industry collaboration opportunities.
"Endometriosis remains one of the most underdiagnosed and underserved conditions in women’s health - yet it affects millions," Sturgess stated in the release.
Ananda Pharma is developing cannabinoid medicines for complex chronic conditions including epilepsy, endometriosis, and chemotherapy-induced peripheral neuropathy. The company reports its endometriosis clinical trials are funded by NHS Scotland, while its epilepsy trials receive funding from NHS England and NIHR, and chemotherapy pain research is supported by NIHR.
The summit, now in its eighth year, brings together biopharma decision makers, scientists, and regulatory affairs experts focused on cannabinoid prescription therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.